MTFBのチャート
MTFBの企業情報
| symbol | MTFB |
|---|---|
| 会社名 | Motif Bio Plc （モチ―フ・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- モチ―フ・バイオは英国のバイオ医薬品企業。臨床段階で、複数薬物耐性バクテリアに起因する致命的な感染症に効果がある抗生物質の開発に従事。同社開発の「Iclaprim」は院内感染性細菌性肺炎の治療に使用される。グラム陽性菌とグラム陰性菌をタ―ゲットにする抗生物質を製薬会社や大学と共同で開発する。本社はロンドン。 Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. |
| 本社所在地 | One Tudor Street London EC47 0AH GBR |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | － |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.motifbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mtfb |
| adr_tso | 1329718 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 9.01 |
| 時価総額（marketcap） | 11980759.18 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
MTFBのテクニカル分析
MTFBのニュース
Motif Bio PLC - Voluntary delisting from the NASDAQ Capital Market - Vox Markets 2019/12/10 07:00:00 VOX Markets
RNS Number: 2765 W Motif Bio PLC 10 December 2019. Confirmation of timing of voluntary delisting from the NASDAQ Capital Market. Motif Bio plc announces that in furtherance of the previously announced voluntary de-listing from the NASDAQ Capital Market for the Company's American Depository Shares, the Company has filed Form 25 with the US Securities and…
Hedge Funds Have Never Been More Bullish On Motif Bio plc (MTFB) 2019/11/30 14:40:06 Yahoo Finance
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on
MOTIF BIO PLC/S (NASDAQ:MTFB) Sees Large Volume Increase 2019/11/16 02:21:20 Modern Readers
MOTIF BIO PLC/S (NASDAQ:MTFB) shares saw unusually-high trading volume on Friday . Approximately 7,264 shares traded hands during trading, a decline of 99% from the previous session’s volume of 695,062 shares.The stock last traded at $0.16 and had previously closed at $0.17. MTFB has been the subject of a number of research reports. ValuEngine raised […]
Motif Bio reaches settlement with former clinical research organisation 2019/11/11 16:31:41 Share Cast
Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut 2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.